| Harsha M Mulchandani, MD | |
|
2545 S Bruce St Ste 200, Las Vegas, NV 89169-1778 | |
| (702) 732-2438 | |
| (702) 733-7876 |
| Full Name | Harsha M Mulchandani |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 30 Years |
| Location | 2545 S Bruce St Ste 200, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023006384 | NPI | - | NPPES |
| 002018723 | Medicaid | NV | |
| 723131 | Medicaid | AZ | |
| 1023006384 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 10286 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cheyenne Dialysis (dva) | Las vegas, NV | Dialysis facility |
| Sunrise Hospital And Medical Center | Las vegas, NV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nkdhc Rudnitsky Pllc | 1557582210 | 43 |
News Archive
"U.S. support for global health has had a major impact around the world, particularly our contributions to fighting malaria through the President's Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis, and Malaria," Rep. Ander Crenshaw (R-Fla.), co-chair of the Congressional Caucus on Malaria and Neglected Tropical Diseases, and Steve Davis, CEO of PATH, write in a Washington Times opinion piece.
Daily probiotic use was associated with fewer upper respiratory symptoms in overweight and older people, according to a study that suggests a potential role for probiotics in preventing respiratory infections.
Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known outside the US and Canada as MSD), and NYU Langone Medical Center are working together to evaluate an approach targeting a novel part of a major surface protein on the malaria parasite. Malaria is estimated to kill close to 900,000 people each year with the majority of deaths occurring in children under the age of five in sub-Saharan Africa.
Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
| Entity Name | Nkdhc Rudnitsky Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265831432 PECOS PAC ID: 1557582210 Enrollment ID: O20141021002605 |
News Archive
"U.S. support for global health has had a major impact around the world, particularly our contributions to fighting malaria through the President's Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis, and Malaria," Rep. Ander Crenshaw (R-Fla.), co-chair of the Congressional Caucus on Malaria and Neglected Tropical Diseases, and Steve Davis, CEO of PATH, write in a Washington Times opinion piece.
Daily probiotic use was associated with fewer upper respiratory symptoms in overweight and older people, according to a study that suggests a potential role for probiotics in preventing respiratory infections.
Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known outside the US and Canada as MSD), and NYU Langone Medical Center are working together to evaluate an approach targeting a novel part of a major surface protein on the malaria parasite. Malaria is estimated to kill close to 900,000 people each year with the majority of deaths occurring in children under the age of five in sub-Saharan Africa.
Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Harsha M Mulchandani, MD 2545 S Bruce St Ste 200, Las Vegas, NV 89169-1778 Ph: (702) 732-2438 | Harsha M Mulchandani, MD 2545 S Bruce St Ste 200, Las Vegas, NV 89169-1778 Ph: (702) 732-2438 |
News Archive
"U.S. support for global health has had a major impact around the world, particularly our contributions to fighting malaria through the President's Malaria Initiative and the Global Fund to Fight AIDS, Tuberculosis, and Malaria," Rep. Ander Crenshaw (R-Fla.), co-chair of the Congressional Caucus on Malaria and Neglected Tropical Diseases, and Steve Davis, CEO of PATH, write in a Washington Times opinion piece.
Daily probiotic use was associated with fewer upper respiratory symptoms in overweight and older people, according to a study that suggests a potential role for probiotics in preventing respiratory infections.
Development of a vaccine to prevent the malaria parasite from entering the human liver is the goal of a new collaboration announced today by global leaders in malaria research and vaccine development. The PATH Malaria Vaccine Initiative (MVI), Merck (known outside the US and Canada as MSD), and NYU Langone Medical Center are working together to evaluate an approach targeting a novel part of a major surface protein on the malaria parasite. Malaria is estimated to kill close to 900,000 people each year with the majority of deaths occurring in children under the age of five in sub-Saharan Africa.
Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
Dr. Arshi A. Quadeer, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2545 S Bruce St Ste 200, Las Vegas, NV 89169 Phone: 702-732-2438 Fax: 702-737-5043 | |
Cherie Lin, D.O. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3006 S Maryland Pkwy, Suite 400, Las Vegas, NV 89109 Phone: 702-369-5582 Fax: 702-369-1533 | |
Michael M Lee, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1800 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-921-6823 Fax: 702-549-5240 | |
Henry Palangdao Igid, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 653 N Town Center Dr Ste 402, Las Vegas, NV 89144 Phone: 702-243-7200 Fax: 702-243-7235 | |
Ian Adrian Fanoga Frani, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1800 W Charleston Blvd, Las Vegas, NV 89102 Phone: 702-383-2000 Fax: 702-383-3875 | |
Sein Tun, DO Nephrology Medicare: Medicare Enrolled Practice Location: 620 Shadow Ln, Las Vegas, NV 89106 Phone: 702-388-4000 | |
Berge Jack Dadourian, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 400 S Rampart Blvd, Suite 240, Las Vegas, NV 89145 Phone: 702-906-1100 Fax: 702-906-1110 |